The Oxionbio Story

Oxion Biologics was founded in 2021 by a team with more than 70 years of combined experience in the medical and biotech sectors. We are a based in Stockholm, Sweden and are on a mission to transform the immunology landscape.

From Stockholm to the World

At Oxion Biologics, we are driven by the pursuit of excellence and efficiency. Our lead development, OX118, embodies this spirit. As a best-in-class drug candidate, OX118 holds the potential to revolutionize patient care and outcomes in a wide range of immune-mediated diseases. OX118 will enter its first-in-human clinical study in April 2025, marking a significant milestone in our journey. Our team is committed to advancing the science of immunology and delivering transformative therapies to patients worldwide.

We invite you to join us on this exciting journey as we continue to push the boundaries of medical science and redefine the future of healthcare.